

BIOGEN IDEC INC.

ISIN: **US09062X1037** WKN: **09062X103**

Overview

| | |
|---------------------|---|
| 2024/07/16 08:00:21 | |
| Price | 203.00 EUR |
| Difference | ▼ -3.84% (-8.10) |

| | |
|---------------------------|------------------------------------|
| General attributes | |
| ISIN | US09062X1037 |
| Symbol | BIIB |
| Exchange | Munich |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 29,603 EUR |
| Benchmark | S&P 500 |

| | |
|--------------------|------------|
| Market data | |
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 203.00 EUR |
| High | 203.00 EUR |
| Low | 203.00 EUR |
| Close (prev. day) | 211.10 EUR |
| VWAP | 200.90 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 2 |
| Last size | 0 |

| | |
|----------------------------|---|
| Futures and Options | |
| Related Futures | - |
| Related Options | - |

| | |
|----------------------------------|-------------------|
| PDF Downloads | |
| Company report: BIOGEN IDEC INC. | ↓ |



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | | on market | |
|------------|--|-----------------------|-------------------|
| Date | | Headline | Download |
| 2024/07/12 | | Global Equity Ratings | ↓ |
| 2024/06/21 | | Global Equity Ratings | ↓ |
| 2024/06/14 | | Global Equity Ratings | ↓ |
| 2024/05/29 | | Global Equity Ratings | ↓ |
| 2024/04/26 | | Global Equity Ratings | ↓ |

Details

2024/07/16 08:00:21

Price

203.00 EUR

Difference 📉 -3.84% (-8.10)

General attributes

ISIN US09062X1037

Symbol BIIB

Exchange Munich

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 29,603 EUR

Benchmark S&P 500

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 203.00 EUR

High 203.00 EUR

Low 203.00 EUR

Close (prev. day) 211.10 EUR

VWAP 200.90 EUR

Volume (pcs) 0

Trading volume 0.00

Number of trades 2

Last size 0

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|---------|
| Perf (%) | -10.96% | -17.81% | -26.99% |
| Perf (abs.) | -25.00 | -44.00 | -75.05 |
| Beta | 0.74 | 0.77 | 0.83 |
| Volatility | 27.40 | 24.99 | 34.86 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.) 211.20 EUR (0)

Ø price 30 days | Ø volume 30 days (pcs.) 211.09 EUR (0)

Ø price 100 days | Ø volume 100 days (pcs.) 202.71 EUR (1)

Ø price 250 days | Ø volume 250 days (pcs.) 220.14 EUR (1)

YTD High | date 243.40 EUR (2024/01/03)

YTD Low | date 177.50 EUR (2024/04/19)

52 Weeks High | date 253.00 EUR (2023/10/17)

52 Weeks Low | date 177.50 EUR (2024/04/19)

All listings for BIOGEN IDEC INC.

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------------------|------------|-------|------------|-----------------------|------------------|
| Xetra | 2024/07/16 | 17:35 | 205.20 EUR | 0.58 | 44 |
| Vienna Stock Exchange | 2024/07/16 | 17:32 | 204.90 EUR | 0.00 | 5 |
| Tradegate | 2024/07/16 | 22:26 | 206.40 EUR | 0.15 | 16 |
| Stuttgart | 2024/07/16 | 21:21 | 205.50 EUR | 0.00 | 9 |
| SIX Swiss Exchange | 2022/ | 17:36 | 222.00 CHF | 0.00 | 1 |

| | | | | | | |
|---|----------------|-------|------------|--------|--|--------|
| | 09/28 | | | | | |
| Nasdaq | 2024/ 07/16 | 22:00 | 225.02 USD | 225.77 | | 24,331 |
| Munich | 2024/ 07/16 | 08:00 | 203.00 EUR | 0.00 | | 2 |
| London Stock Exchange | 2024/ 07/02 | 15:49 | 229.07 USD | 0.01 | | 1 |
| Hanover | 2024/ 07/16 | 08:48 | 202.90 EUR | 0.00 | | 3 |
| Hamburg | 2024/ 07/16 | 16:43 | 205.80 EUR | 0.01 | | 2 |
| Frankfurt | 2024/ 07/16 | 17:00 | 206.80 EUR | 0.62 | | 5 |
| Euronext Milan MTF Trading After Hours | 2024/ 05/30 | 18:01 | 201.30 EUR | 0.00 | | 1 |
| Euronext Milan MTF Global Equity Market | 2024/ 07/16 | 17:44 | 204.80 EUR | 0.00 | | 1 |
| Duesseldorf | 2024/ 07/16 | 19:31 | 205.10 EUR | 0.00 | | 7 |
| Berlin | 2024/ 07/16 | 20:21 | 206.20 EUR | 0.00 | | 18 |

Company profile

Company Logo



Contact Details

BIOGEN INC.

--

225 Binney Street - 02142 Cambridge

Telefon: +1-617-679-2000

Fax: +

E-mail: info@biogen.com

PDF Downloads

Company report: BIOGEN IDEC INC. 

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Members of Management Board

Caroline Dorsa Chairman of Board of Directors

Eric Rowinsky Member of Board of Directors

Maria Freire Member of Board of Directors

Stephen Sherwin Member of Board of Directors

Jesus Mantas Member of Board of Directors

Monish Patolawala Member of Board of Directors

Susan Langer Member of Board of Directors

William Hawkins Member of Board of Directors

Chris Viehbacher Chairman of Managing Board

Ginger Gregory Member of Executive Committee

Michael McDonnell Member of Executive Committee

Nicole Murphy Member of Executive Committee

Priya Singhal Member of Executive Committee

Rachid Izzar Member of Executive Committee

Susan H. Alexander Member of Executive Committee